MLND
Millendo Therapeutics, Inc. [MLND] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MLND Stock Summary
In the News
MLND Financial details
Company Rating
-
Market Cap
11.15M
Income
-38.12M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
12
Optionable
No
Shortable
Yes
Earnings
09 Nov 2020
P/E
-0.04
Forward P/E
-
PEG
0.01
P/S
-
P/B
0.04
P/C
-
P/FCF
-0.37
Quick Ratio
4.82
Current Ratio
5.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-30.37
EPS next Y
-
EPS next Q
-
EPS this Y
-40.64%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-45.01%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
-15.73%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
-84%
ROE
-78%
ROC
-1.02%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.06-1.13
52W High
+6%
52W Low
+6%
RSI
28
Rel Volume
13.57
Avg Volume
140.98K
Volume
1.91M
Perf Week
-42.39%
Perf Month
-19.7%
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
0.476276
-
-
Volatility
0.27%, 0.22%
Prev Close
-40.11%
Price
1.06
Change
-39.43%
Company Profile
- Volume Average 140.98K
- Market Capitalization 11.15M
- Employee 12
- CEO Dr. Julia Owens
- Headquarters Ann Arbor,MICHIGAN,US
- IPO Date 2012-10-04
-
Website
http://www.millendo.com 
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
